Granulomatous hepatitis as a late complication of BCG immunotherapy

A case of BCG-induced granulomatous hepatitis, which developed 1 1/2 years after BCG immunotherapy for recurrent malignant melanoma, is described to document the development of this disease entity as a potential late complication of BCG immunotherapy. The clinical implications of the late development of BCG-induced granulomatous hepatitis, use of immunosuppressive chemotherapy, and possible alternatives for BCG in intratumor immunotherapy are discussed.